DNM1P41: A Potential Drug Target Or Biomarker (G440299)

Target Name: DNM1P41

NCBI ID: G440299

DNM1P41

Other Name(s): DNM1DN11-6 | dynamin 1 pseudogene 41 | DNM1DN11@ | Dynamin 1 pseudogene 41 | DNM1DN11.6

DNM1P41: A Potential Drug Target Or Biomarker

DNM1P41 (DNM1DN11-6) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its primary function is to regulate the growth and differentiation of neural stem cells, which are responsible for the development and maintenance of the nervous system.

DNM1P41 has been identified as a potential drug target or biomarker due to its unique biology and the involvement of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of DNM1P41 is its role in the regulation of stem cell proliferation and differentiation. Neural stem cells are a type of stem cell that have the ability to develop into different types of cells in the nervous system, including neurons and glial cells. DNM1P41 plays a crucial role in the survival and proliferation of these stem cells by regulating the levels of several key genes that are involved in cell growth and differentiation.

In addition to its role in stem cell biology, DNM1P41 has also been linked to several diseases and conditions. For example, DNM1P41 has been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that it may be a useful biomarker for these diseases and may also be a potential drug target for cancer treatment.

Another potential application of DNM1P41 is its role in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and are often associated with significant decline in cognitive function and quality of life. DNM1P41 has been shown to be involved in the regulation of the production and function of neurotransmitters, which are involved in the regulation of mood, appetite, and other aspects of brain function. Therefore, DNM1P41 may be a useful target for therapies aimed at treating neurodegenerative diseases.

In addition to its potential applications in cancer and neurodegenerative diseases, DNM1P41 is also being studied for its potential as a drug target for autoimmune disorders. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. DNM1P41 has been shown to be involved in the regulation of immune cell function and has been suggested as a potential target for treatments aimed at treating autoimmune disorders.

Overall, DNM1P41 is a protein that has significant potential as a drug target or biomarker due to its unique biology and involvement in several diseases. Further research is needed to fully understand its role and potential applications in medicine.

Protein Name: Dynamin 1 Pseudogene 41

The "DNM1P41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNM1P41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets